At a glance

ClinicalIndex Comparison Record

Phase 1Completed· 19 enrolled

Drug / intervention

KQ-791 +2 moredrug

Likely dose

Not stated in record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02370043

NCT02370043Phase 1Completed

Compare CT.gov

Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of KQ-791 in Healthy Subjects

Kaneq Bioscience Limited·interventional·Posted Feb 24, 2015·Updated Nov 26, 2019

In Brief

A Phase 1 clinical trial evaluating KQ-791, KQ-791 (after meal), and 1 other intervention for Healthy Volunteers and Insulin Resistance. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

The purpose of this study is to assess the safety, tolerability, and the effect of food on KQ-791. Each participant may receive up to 3 single doses of KQ-791 (at up to 3 different dose levels) and 1 placebo dose over the course of the study. Up to 6 escalating dose levels may be studied, in two distinct groups or cohorts.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsHealthy Volunteers, Insulin Resistance

CountriesCanada

Collaborators--

Timeline

Phase 1CompletedFinished

201520162017201820192020202120222023202420252026

Enrollment StartFeb 2015

First PostedFeb 2015

Primary CompletionJul 2015

TodayJul 2026

First PostedFeb 24, 2015

Enrollment StartFeb 1, 2015

Primary CompletionJul 1, 2015

TodayJul 2, 2026

Enrollment to primary: 5 monthsPosted 11.4 years ago

Interventions

KQ-791drug

Capsules administered orally while fasting, in up to 3 periods

KQ-791 (after meal)drug

Single dose of KQ-791 in capsules, after a meal, in 1 period

Placebodrug

Capsules, administered orally, in 1 period